secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001493152-23-033213
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 2.03, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAffinity completes $3.5M acquisition of clinical lab; issues 564,972 shares; appoints Dr. Joyce to board
--------------------------------------------------------------------------------

- Acquired a CAP-accredited, CLIA-certified clinical pathology lab from Village Oaks Pathology for $3.5M ($2.5M cash + 564,972 restricted shares).
- Dr. Roby Joyce appointed to Board of Directors and as Medical Director of subsidiary PPLS under a 3-year employment agreement at $333,333/year.
- Xavier Reveles promoted to COO effective Sept 18, 2023; base salary raised from $150,000 to $175,000.
- Warrant amendments delay exercise until authorized common stock is increased to cover all outstanding warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223033213/0001493152-23-033213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223033213/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer